Protagonist Therapeutics Inc (PTGX)

Net profit margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	162,110	-78,955	-140,484	-137,611	-140,188	-127,393	-130,106	-132,678	-122,483	-125,551	-107,530	-81,489	-70,068	-66,150	-64,765	-73,411	-83,164	-77,187	-73,551	-65,877
Revenue (ttm)	US$ in thousands	315,090	60,137	123	123	982	26,704	35,221	45,507	46,913	27,380	24,330	27,139	31,091	28,549	25,678	12,604	6,408	4,321	3,955	10,051
Net profit margin		51.45%	-131.29%	-114,214.63%	-111,878.86%	-14,275.76%	-477.06%	-369.40%	-291.56%	-261.09%	-458.55%	-441.96%	-300.27%	-225.36%	-231.71%	-252.22%	-582.44%	-1,297.82%	-1,786.32%	-1,859.70%	-655.43%

March 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $162,110K ÷ $315,090K
= 51.45%

The net profit margin of Protagonist Therapeutics Inc has shown significant fluctuations over the past few quarters, with some periods reporting extremely high negative margins. Specifically, the net profit margin was exceptionally low in a number of quarters, with the figures indicating losses far exceeding revenues. This volatility in net profit margin suggests potential challenges in the company's ability to generate profits and manage expenses effectively. Further analysis and investigation into the company's financial performance and cost structure may be necessary to identify and address underlying issues impacting profitability.